Sun Pharmaceutical industries share price has declined 4-5% in 2 trading sessions following OAI status determined by the ...
Sun Pharma said that the US FDA conducted an inspection at the company's Dadra facility from December 4, 2023 to December 15, 2023. The US FDA has subsequently determined the inspection ...
Image Source : FILE Business stock exchange building. In today’s trading session, the Indian stock market witnessed a decline, with the Sensex plummeting by 250 points and the Nifty slipping ...
From the Sensex pack, NTPC, L&T and Mahindra and Mahindra were among the major gainers in the morning session whereas, Sun Pharma, HCL and Infosys were among the laggards. The Indian rupee opened ...
The Food and Drug Administration published an expanded import alert Wednesday to stop all plastic syringes made by a Chinese manufacturer from entering the U.S. On March 28, the FDA issued an ...
The Food and Drug Administration published an expanded import alert Wednesday to stop all plastic syringes made by a Chinese manufacturer from entering the U.S. On March 28, the FDA issued an ...
Sun Pharma Advanced Research Company Ltd. (SPARC) on Wednesday announced that it is abandoning the Phase 2 study on Vodobatinib for Parkinson’s Disease. According to the company’s exchange ...
Shares of Sun Pharma Advanced Research Company (SPARC ... experts before taking any investment decisions. Advisory Alert: It has come to our attention that certain individuals are representing ...
Sun Pharma Advanced Research Company Ltd. announced the results of the interim analysis from the Proseek study, a global Phase 2 study in patients with early Parkinson’s Disease. The study ...
On April 10, Sun Pharma Advanced Research Company (SPARC) shares dropped 5% to reach the lower circuit following the Mumbai-based pharmaceutical company's announcement that it was giving up on its ...
One member of the FDA advisory committee was linked to hundreds of payments from Abbott totaling almost $200,000, according to the database maintained by the federal Department of Health and Human ...
Mumbai-based pharmaceutical company, Sun Pharma Advanced Research Company Ltd. (SPARC), said it was abandoning its Phase 2 study on Vodobatinib for Parkinson's. The study was designed to evaluate ...